MedVi vs Hers: Compounded Semaglutide vs FDA-Approved Wegovy
MedVi vs Hers at a glance: MedVi sells clinically dosed compounded semaglutide starting at $179 for a promotional first month with no clinic visits and 24/7 certified medical support. Hers offers FDA-approved Wegovy and other brand-name GLP-1s, with prices from $149 for the Wegovy pill or $199 for injectables and a required membership to access medication. Early verdict: choose MedVi if you want a no-clinic, compounded semaglutide path with a low promotional first month; choose Hers if you want FDA-approved, brand-name Wegovy and a personalized care team.
How they differ: compounded versus brand-name medications
MedVi provides clinically dosed compounded semaglutide. The provider explicitly states compounded medications are not FDA-approved and are not reviewed by FDA for safety, effectiveness, or quality. MedVi highlights that compounded GLP-1s use the same active ingredients as Ozempic and Wegovy and are produced in FDA-regulated facilities, while also warning the medications themselves are not FDA-approved.
Hers, by contrast, markets FDA-approved Wegovy as a brand-name option and states it does not offer compounded medications for Wegovy. Hers emphasizes using doctor-trusted, brand-name GLP-1s and notes Wegovy and Zepbound are FDA-approved for weight loss.
Pricing and membership structure
MedVi lists a winter promotional first-month price of $179 including fast, free shipping, and notes a standalone month costs $299 after the promotion. A three-month plan is available at $649, about $216 per month. MedVi operates on a cash-pay model and does not bill insurance.
Hers lists Wegovy options from $149/month for the pill and $199/month for injectables, but requires an active Hers Weight Loss Membership to access medication. The membership is $39 for the first month and auto-renews at $149/month thereafter, and medication and membership are billed separately. Hers says medication is not available without an active membership.
Care model and clinician involvement
MedVi promotes a simple online process with no clinic visits needed. A licensed clinician reviews the online intake and OpenLoop Health clinicians meet with individuals after checkout to determine eligibility and whether to prescribe compounded GLP-1s. MedVi also highlights 24/7 support from certified medical professionals.
Hers advertises a personalized care team with ongoing dose check-ins and states treatment is available only when a licensed clinician determines it is medically appropriate. Hers emphasizes state availability limits and that a prescription is required.
Regulatory and safety notes to compare
Both providers include regulatory notes. MedVi explicitly says compounded medications are not FDA-approved and are not reviewed by FDA for safety, effectiveness, or quality, while also noting its compounded GLP-1s are produced in FDA-regulated facilities. Hers stresses that Wegovy and Zepbound are FDA-approved for weight loss and that some brand drugs are approved only for type 2 diabetes and may be prescribed off-label for weight loss at a clinician’s discretion.
Distinctive differences summarized
From the supplied facts, the three most distinctive supported differences are medication type, pricing and membership, and care delivery method. MedVi: compounded semaglutide, low first-month promo, no clinic visits, 24/7 certified support. Hers: FDA-approved Wegovy and other brand GLP-1s, membership required to access medication, personalized care team with dose check-ins.
Quick comparison table
| Criterion | MedVi | Hers |
|---|---|---|
| Medication type | Compounded semaglutide | FDA-approved Wegovy and brand-name GLP-1s |
| Starting price | Starting at $179 first month (promo) | Wegovy pill from $149/mo; injectable from $199/mo |
| Membership required | No membership required | Yes; active membership required to access medication |
| Care model | Online intake, no clinic visits, 24/7 certified support | Personalized care team with ongoing dose check-ins |
| Regulatory note | Compounded meds are not FDA-approved | Wegovy and Zepbound are FDA-approved for weight loss |
Patient experience and outcomes language
MedVi presents self-reported data from GLP-1 customers on compounded medication plans and notes results vary based on adherence and clinician recommendations. MedVi reports typical weight loss of 1-2 lbs per week after 4 weeks for patients who reached and maintained a 2.4 mg/week dose, while qualifying that results vary and are not guaranteed. Hers shows example weight-loss milestones on its site but captured FAQ detail was limited in the supplied evidence. Hers emphasizes that prescription and eligibility are determined by a licensed clinician.
Conclusion: MedVi vs Hers
MedVi vs Hers comes down to whether you prioritize a low promotional first-month price and a no-clinic, compounded semaglutide program with 24/7 support, or whether you prefer FDA-approved, brand-name Wegovy with a personalized care team and a membership model. Both include clinician review and note prescriptions are subject to clinician determination.
Choose MedVi if…
you want compounded semaglutide with a simple online process, no clinic visits, 24/7 certified medical support, and a promotional first month starting at $179.
Choose Hers if…
you want FDA-approved Wegovy or other brand-name GLP-1s, a personalized care team with dose check-ins, and are prepared to use a paid membership to access medication.